Ferring, Aventis Reach $20M Deal In DDAVP Antitrust Suit

Law360, New York (August 4, 2011, 3:50 PM EDT) -- Ferring BV and Aventis Pharmaceuticals Inc. on Wednesday agreed to pay $20.25 million to settle with a proposed class of direct purchasers of DDAVP who claimed in a New York suit that the companies suppressed generic competition by fraudulently acquiring a patent for the diabetes drug.

Attorneys for the proposed class sought preliminary approval of a deal that calls for Ferring to shell out $16.75 million and Aventis to cough up $3.5 million to resolve allegations that the companies violated the Sherman Act.

The lawsuit, filed...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.